Clinical trial · Interventional
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer. The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected. The prospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 Chinese hospitals from January 2024 to April 2027 were enrolled.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Thyroid Cancer Patients Who Received Target Therapy | — | UNRESOLVED | — |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| anlotinib or anlotinib plus anti-PD-1 antibody | Drug | — | UNRESOLVED |
| dabrafenib plus trametinib with or without PD-1 antibody | Drug | — | UNRESOLVED |
| entrectinib or larotrectinib with or without anti-PD-1 antibdoy | Drug | — | UNRESOLVED |
| lenvatinib plus anti-PD-1 antibody | Drug | — | UNRESOLVED |
| Other Targets: precise treatment based on the target | Drug | — | UNRESOLVED |
| pralsetinib or selpercatinib with or without anti-PD-1 antibdoy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- type
- EXPERIMENTAL
- label
- Radioiodine-refractory differentiated thyroid cancer
- description
- advanced or metastatic thyroid cancer patients who are refractory to radioiodine treatment
- interventionNames
- Drug: dabrafenib plus trametinib with or without PD-1 antibody
- Drug: entrectinib or larotrectinib with or without anti-PD-1 antibdoy
- Drug: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
- Drug: anlotinib or anlotinib plus anti-PD-1 antibody
- Drug: lenvatinib plus anti-PD-1 antibody
- Drug: Other Targets: precise treatment based on the target
- type
- EXPERIMENTAL
- label
- Differentiated thyroid carcinoma not suitable for radioiodine therapy
- description
- advanced or metastatic differentiated thyroid cancer patients who are not suitable for radio iodine therapy, for example, DTC patients with huge neck tumor but cannot receive the thyroid ectomy
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Patients volunteered to participate in this study and signed informed consent; 2. Each center can be enrolled in patients who meet the age of their own practice range, regardless of gender ; 3. Histologically diagnosed locally advanced or recurrent / metastatic thyroid cancer that cannot undergo radical surgery meets one of the following requirements: 1. Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC); 2. Differentiated thyroid carcinoma not suitable for iodine therapy; 3. Medullary thyroid carcinoma (MTC); 4. poorly differentiated thyroid cancer (PDTC) or anaplastic thyroid cancer (ATC); 4. Thyroid-related pathogenic or therapeutic target gene detection was performed before enrollment. Exclusion Criteria: 1. Patients who are participating in clinical trials of other drugs; 2. There is evidence that the patients are pregnant or lactating; 3. Other situations that are not suitable for inclusion in this study.
References
Publications (0)
Data not yet available